• Bioscientia Acquires Multiple Revio Sequencing Systems to Revolutionize Rare Disease Research by Sequencing Thousands of Long-Read Human Genomes Annually
  

MENLO PARK, Calif., June 28, 2023 /PRNewswire/ -- PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced that Bioscientia is using its Revio long-read sequencing systems to expand its genomics research projects and sequence several thousand human genomes per year. Part of Sonic Healthcare Group, Bioscientia is a leading global provider of clinical laboratory testing services for diagnostics based in Germany. The increased accuracy, read length and methylation insights offered by the Revio system will enable Bioscientia to explore certain monogenic disorders, such as deafness, blindness, and developmental delay, and study the underlying causes of rare diseases.

"Bioscientia is a world-leading provider of testing services, and we are thrilled that they have chosen Revio to explore the potential clinical use of long-read sequencing," said Christian Henry, President and Chief Executive Officer of PacBio. "Revio will help enable Bioscientia to deliver more insights to families with fewer tests, lower overall costs, and less time spent assembling genome maps. This research is vital for advancing our understanding of the role genetics plays in rare diseases and developmental disorders. Working with companies like Bioscientia is an important step in achieving PacBio's mission to enable the promise of genomics to better human health."

Whole-genome sequencing using the Revio system enables the consolidation of multiple tests into a single, comprehensive solution, replacing the time-consuming and costly multi-stage vetting process for rare diseases and developmental delay disorders. Previously, separate experiments like chromosome analysis, optical genome mapping, and short-read exome sequencing were required. By leveraging Revio technology, researchers can now obtain vital data faster and more efficiently. This advancement helps to reduce costs, improve accessibility, and offer hope for families to better understand the genetic underpinning of certain rare diseases, potentially transforming the landscape of rare disease diagnosis and developmental delay assessment.

"Revio will enable us to answer questions we previously could not solve with just exome sequencing – helping us to tackle many unsolved or partially solved cases," commented Professor Hanno Bolz, M.D., Head of Human Genetics at Bioscientia. "Purchasing these new Revio systems will significantly expand Bioscientia's genomics capabilities. Results that previously required several tests can now be completed in a single run with Revio. Haplotype phasing is possible on an individual sample, and no longer requires familial segregation analysis. HiFi reads cover repetitive regions, genes with pseudogene backgrounds and allow for methylation analysis – so we can uncover imprinting defects. We believe this technology will benefit families by giving greater clarity in underlying causes of diseases and, ultimately, shortening the diagnostic odyssey they face."

Bioscientia will also use Revio for extended testing of partially solved samples and recessive disease scenarios. These are situations where Bioscientia's existing short-read exome sequencing technologies have not been able to provide more complete, definitive explanations. HiFi sequencing provides a highly accurate complete sequence of the genome, meaning that structural variations and even "hidden" gene mutations in complex and difficult-to-sequence regions are identified with greater confidence.

"Bioscientia has been a pioneer of innovation in complex diagnoses for more than 50 years, and we look forward to helping it advance its mission," said Jeff Eidel, Chief Commercial Officer at PacBio. "PacBio's sequencing technologies are among the most accurate and complete available today. Combined with advances in throughput and cost, we believe Revio will empower the Bioscientia team to further accelerate its field-leading research across many applications in genomics."

About PacBio

PacBio (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long-read sequencing and our emerging SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies; Bioscientia's use of PacBio's long-read sequencing technology to sequence several thousand genomes per year, explore certain monogenic disorders, deliver more insights to families, and reduce the amount of testing, costs and time to obtain rare disease-related genomic answers for families; and other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this press release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements, including challenges inherent in developing, manufacturing, launching, marketing and selling new products; potential product performance and quality issues; rapidly changing technologies and extensive competition in genomic sequencing; and third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights. Readers are strongly encouraged to read the full cautionary statements contained in PacBio's filings with the Securities and Exchange Commission, including the risks set forth in PacBio's Forms 8-K, 10-K, and 10-Q. PacBio disclaims any obligation to update or revise any forward-looking statements.

Contacts

Media:
Lizelda Lopez
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investors:
Todd Friedman
This email address is being protected from spambots. You need JavaScript enabled to view it.